Arcus Biosciences, Inc. (RCUS) NYSE
24.02
-1.65(-6.43%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Arcus Biosciences, Inc.
Address
3928 Point Eden Way
Hayward, CA 94545
United States of America (the)
Phone
510 694 6200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
627
First IPO Date
March 15, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Terry J. Rosen | Co-Founder, Chairman & Chief Executive Officer | 1.45M | 1960 |
| Carolyn C. Tang | General Counsel & Corporate Secretary | 603,200 | 1979 |
| Robert C. Goeltz | Principal Financial Officer & Chief Financial Officer | 792,694 | 1973 |
| Richard A. Markus | Chief Medical Officer | 933,883 | N/A |
| Jennifer A. Jarrett | Advisor | 1M | 1971 |
| Juan Carlos Jaen | Co- Founder & President | 1.01M | 1958 |
| Holli Kolkey | Vice President of Corporate Communications | 0 | N/A |
| Alexander Azoy | Chief Accounting Officer | 0 | 1976 |
| Yvonne Gehring | Senior Vice President of Human Resources | 0 | N/A |
| K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Pia Eaves | Vice President of Investor Relations & Strategy | 0 | N/A |
| Jonathan Yingling | Chief Scientific Officer | 0 | 1969 |
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
